PRX-112 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
19	Lysosomal storage disease	2

19. Lysosomal storage disease

---

Clinical trials : 854 /  Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02107846 (ClinicalTrials.gov)	April 2014	4/4/2014	An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112	A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Naïve Subjects With Gaucher Disease	Gaucher Disease	Drug: PRX-112	Protalix	NULL	Completed	18 Years	N/A	Both	10	Phase 2	Israel
2	NCT01747980 (ClinicalTrials.gov)	March 2013	5/12/2012	Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients	An Exploratory, Open-label Study to Evaluate the Safety of PRX-112 and Pharmacokinetics of Oral prGCD (Plant Recombinant Human Glucocerebrosidase) in Gaucher Patients	Gaucher Disease	Drug: PRX-112	Protalix	NULL	Completed	18 Years	N/A	Both	16	Phase 1	Israel